As a trustee, Dr. Ehrlich has put the TMA’s mission and vision at the forefront of her efforts to improve the circumstances of the practice of medicine by striving to keep TMA’s strength as her top priority. Houston, TX – … Continue reading
|
|
Houston Natural Resources (OTC: HNRC) Strengthens Global Energy Market Presence Houston Natural Resources Corporation (OTC: HNRC) stands out as a leading entity in the oil and gas industry, marked by strategic acquisitions such as Cunningham Energy, investments in HNR Acquisition Corp. (NYSE: HNRA) and a notable stake in Rhino Energy, … Continue reading
|
|
Stocks on The Street Under 10¢ in Focus: FFIE, SPZI, HNRC, PEGY, HALB It is crucial for investors to diligently research to identify stocks worth monitoring. Given the vast array of stocks available, this task can often be challenging. This overview delves into five stocks that might be worth watching currently. Faraday … Continue reading
|
Rheumatoid Arthritis Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) DelveInsight’s, “Rheumatoid Arthritis Pipeline Insight 2024” report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis therapeutics assessment … Continue reading
|
|
Oncolytic Virus Cancer Therapy Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight 2024” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment … Continue reading
|
Osteoarthritis Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) DelveInsight’s, “Osteoarthritis Pipeline Insight 2024” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis therapeutics assessment by product type, stage, … Continue reading
|
|
Ocular Hypertension Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) DelveInsight’s, “Ocular Hypertension Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, … Continue reading
|
DelveInsight’s, “Non-Alcoholic Fatty Liver Disease Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading
|
|
DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insight 2024” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, … Continue reading
|
Melanoma Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) DelveInsight’s, “Melanoma Pipeline Insight 2024” report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of … Continue reading
|